Merus B.V. [ ] Common Shares1 (nominal value €0.09 per share) Underwriting AgreementUnderwriting Agreement • May 9th, 2016 • Merus B.V. • Pharmaceutical preparations • New York
Merus B.V., a limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ ] common shares, nominal value €0.09 per share (the “Common Shares”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ ] additional Common Shares to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the cont
MERUS N.V. INDEMNIFICATION AGREEMENTIndemnification Agreement • May 9th, 2016 • Merus B.V. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20[16] between Merus N.V., a public company with limited liability incorporated under the laws of the Netherlands (the “Company”), and [Name] (“Indemnitee”).
Lessor Stichting Incubator Utrecht Yalelaan 40 Lessee Merus B.V. Padualaan 8 The Netherlands Property Yalelaan 62, 3584 CM, in Utrecht Lease period 5 years Commencement date of the lease 4th quarter of 2016 (to be determined definitively, by mutual...Lease Agreement • May 9th, 2016 • Merus B.V. • Pharmaceutical preparations
That office and laboratory spaces in the LSI are offered based on market conditions, taking into account the issued ERDF grant;
